A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).
Ting Wang(Xuzhou Medical College), Qing Zhou(Sichuan University), Lin Huang(Sun Yat-sen University), Yongsheng Wang(Guangzhou University of Chinese Medicine), Xi Zheng(Sichuan University), Li Jiang(Shanghai Jiao Tong University), Dan Pu(Sichuan University), Ping Zhou(Capital Medical University), Ming Yang Feng(Sichuan University), Han Deng(Sichuan University), Lu Li(Chinese PLA General Hospital), Wei Ya Wang(Sichuan University), Xue Jin Ou(Sichuan University), Jie Wei Liu(Sichuan University), Da Zhu(Sichuan University), Ming Su(Sichuan University), Long Tian(Sichuan University), Xincheng Cai(Sichuan University)
Cited by 3
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
|Clinical Cancer Research|2018|198
Studies on the structure-activity relationship and interaction mechanism of flavonoids and xanthine oxidase through enzyme kinetics, spectroscopy methods and molecular simulations
|Food Chemistry|2020|156
Tumor-derived Exosomes Induced M2 Macrophage Polarization and Promoted the Metastasis of Osteosarcoma Cells Through Tim-3
|Archives of Medical Research|2020|91